Publications

19 Apr 2010
Research & Ideas

The History of Beauty

chypre, and was the first perfumer to sell his wares in elegantly designed glass bottles, rather than in the pharmaceutical bottles used previously. An ambitious believer in globalization, he even sent his energetic mother-in-law to open... View Details

Keywords: by Sean Silverthorne; Beauty & Cosmetics

01 Sep 2007
News

Alfred D. Chandler Jr. Remembered

England, and Germany by examining the 200 largest corporations in those countries. In 2001, Chandler wrote Inventing the Electronic Century: The Epic Story of the Consumer Electronics and Computer Industries, which focused on the fall of the Radio Corporation of View Details

John T. Gourville

John Gourville is the Albert J. Weatherhead, Jr. Professor of Business Administration at the Harvard Business School. He joined the HBS Marketing Unit in 1995 after receiving his Ph.D. at the University of Chicago in marketing and behavioral research. His most... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

March 2023 (Revised March 2023)
Case

Roche: Innovation and Access to Healthcare

By: George Serafeim, Susanna Gallani and Benjamin Maletta

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details

Elon Kohlberg is the Royal Little Professor of Business Administration at the Harvard Business School. His research is mainly in Game Theory, in particular the study of non-cooperative equilibrium.

Professor Kohlberg has taught many courses in the MBA,... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

September 2010 (Revised July 2013)
Case

Alnylam Pharmaceuticals: Building Value from the IP Estate

By: Willy C. Shih and Sen Chai

The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details

Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States

October 2022
Case

Cost Plus Drugs

By: Alexander MacKay and James Barnett

In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details

Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Pharmaceutical Industry; Pharmaceutical Industry; United States; Texas

February 2024
Case

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu

This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details

Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom

Web

Request more information | HBS Courses | HBS Online

Aerospace/Defense Agriculture Auto Communications E-Commerce E-Education Energy Entertainment Financial Services Food/Beverage Health/Medical Hospitality Insurance Manufacturing Non-Profit Pharmaceuticals Professional Services Retail... View Details

January 2017
Case

The Six CEOs of Tyco International Ltd.

By: John R. Wells and Gabriel Ellsworth

In September 2016, Johnson Controls, Inc. completed the acquisition of Tyco International PLC, a $9.9 billion business with operating profits of $884 million. The purchase consideration was $14.4 billion. Although the deal was billed as a merger, Ireland-based Tyco... View Details

November 2016
Case

Transformation at Eli Lilly & Co. (A)

By: William R. Kerr and Alexis Brownell

Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,... View Details

Keywords: Eli Lilly; Restructuring; R＆D; Transformation; Organizational Change and Adaptation; Organizational Structure; Pharmaceutical Industry; Indianapolis

December 2005 (Revised August 2006)
Case

Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug

By: Felix Oberholzer-Gee and Dennis A. Yao

Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details

Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; United States

November 2020
Case

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher

When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details

Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States

October 2021 (Revised October 2022)
Case

The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni

In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details

June 2023 (Revised June 2023)
Supplement

Roche: ESG and Access to Healthcare

By: George Serafeim

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details

January 2014 (Revised June 2015)
Case

Amgen Inc.: Pursuing Innovation and Imitation? (A)

By: Ian W. Mackenzie

Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:... View Details

Keywords: Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States